All news from Physical Medicine & Rehabilitation

Personalized Treatment Delivered with Aid of 3D-Printed Implant

Southwest Research Institute (SwRI) and The University of Texas at San Antonio (UTSA) are developing a 3D printed implant that, when injected in a patient's body, could deliver a personalized dose of medicine to treat infections as well as ailments such as arthritis, cancer and AIDS.

The project, led by Albert Zwiener of SwRI's Chemistry and Chemical Engineering Division and Dr. Lyle Hood of UTSA's College of Engineering, is supported by a $125,000 grant from the Connecting through Research Partnerships (Connect) program.

Health Risks in Bangladesh: Displacement and Poverty Major Factors

Bangladesh is the tenth most densely populated country in the world, with a population of 166 million people living in a land area of approximately 147,560 square kilometers. Between 2010 and 2016, urban poverty rates declined from 21.3% to 18.9%, and rural poverty rates declined from 35.2% to 26.4%. However, in recent years the rate of poverty reduction in Bangladesh has slowed.

Approximately one in four Bangladeshis (24.3% of the population) remain in poverty and 12.9% of the population lives in extreme poverty. The poverty rates and health risks in Bangladesh are directly affected by the country’s high number of internally displaced persons, refugees, and migrants.

HIV-infected Infants: Initiation of Early Treatment has Undeniable Benefits

The initial findings of the ANRS CLEAC study coordinated by Pierre Frange (Hôpital Necker – AP-HP), help define the immunological and virological benefits of early antiretroviral therapy in HIV-infected children living in France.

The results of this study will be presented by Florence Buseyne (Oncogenic Virus Epidemiology & Pathophysiology Team – Institut Pasteur) this Wednesday, 25 July at the 22nd International AIDS Conference (AIDS 2018) being held in Amsterdam from 23 to 26 July 2018.

OS Benefit in NSCLC With Broad-Based Testing

In community oncology practices, where most cancer in the United States is treated, broad-based genetic testing does not offer survival advantages compared with routine genetic testing for patients with advanced non-small cell lung cancer (NSCLC), concludes a new retrospective study.

But lung cancer experts challenge this conclusion, pointing out that few of the patients who were found to have actionable mutations on broad-based genetic testing actually received targeted therapy and some received targeted therapy not matched to the mutations.